AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Zymeworks Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG019XSYC98
28.22▼ 0.22 (-0.77%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
28.44
Day's Range
27.28 – 28.77
52-Week Range
16.00 – 31.34
Volume
1.1M
Avg Volume
923.9K
Share Statistics
Shares Outstanding
Employees
264
Exchange
XNAS
Listed
2017-04-28
Share count as of August 4, 2026

Zymeworks Inc. (ZYME) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Zymeworks Inc. (ZYME)
What is Zymeworks Inc.'s Market Cap?
Zymeworks Inc.'s Market Cap is $2.0B, based on as-reported figures from SEC (XBRL) filings.
What is Zymeworks Inc.'s Enterprise Value?
Zymeworks Inc.'s Enterprise Value is $1.8B, based on as-reported figures from SEC (XBRL) filings.
What is Zymeworks Inc.'s Price / Sales?
Zymeworks Inc.'s Price / Sales is 53.9×, based on as-reported figures from SEC (XBRL) filings.
What is Zymeworks Inc.'s EV / Revenue?
Zymeworks Inc.'s EV / Revenue is 49.1×, based on as-reported figures from SEC (XBRL) filings.
What is Zymeworks Inc.'s EV / EBITDA?
Zymeworks Inc.'s EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Zymeworks Inc.'s Revenue (TTM)?
Zymeworks Inc.'s Revenue (TTM) is $37.1M, based on as-reported figures from SEC (XBRL) filings.
What is Zymeworks Inc.'s Net Income (TTM)?
Zymeworks Inc.'s Net Income (TTM) is -$150.0M, based on as-reported figures from SEC (XBRL) filings.
What is Zymeworks Inc.'s EBITDA?
Zymeworks Inc.'s EBITDA is -$150.7M, based on as-reported figures from SEC (XBRL) filings.
What is Zymeworks Inc.'s Diluted EPS (TTM)?
Zymeworks Inc.'s Diluted EPS (TTM) is -2.11, based on as-reported figures from SEC (XBRL) filings.
What is Zymeworks Inc.'s EBITDA Margin?
Zymeworks Inc.'s EBITDA Margin is -405.8%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · ZYMEAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue
Research and development collaborations
YoY growth-90.6%-91.1%-91.9%+72.6%
Operating expenses:
Research and development
General and administrative
Total operating expenses
% of revenue1019.0%2056.7%1855.5%180.1%
Loss from operations
% of revenue-919.0%-1956.7%-1755.5%-80.1%
Other (expense) income:
Interest income
Interest expense related to sale of future royalties——
Other income (expense), net
Total other (expense) income, net
(Loss) income before income taxes
Income tax recovery (expense)
Net (loss) income
% of revenue-980.8%-1834.0%-1638.5%-71.0%
Other comprehensive (loss) income:
Unrealized (loss) income on available for sale securities, net of tax of $0
Total other comprehensive (loss) income
Comprehensive (loss) income
Net (loss) income per common share:
Basic (in dollars per share)
Diluted (in dollars per share)